Non-covalent modification of microparticles and process of preparing same

• US 20100009007A1
• Filed: 07/10/2008
• Published: 01/14/2010
• Est. Priority Date: 07/10/2008
• Status: Abandoned Application

• Current Assignee: Baxter Healthcare SA (Baxter International Inc.), Baxter International Inc.
• Original Assignee: Baxter Healthcare SA (Baxter International Inc.), Baxter International Inc.
• Inventors: Scott, Terrence L., Darvari, Ramin, Rashba-Step, Julia E.
• Application Number:
  US12/170,792
• Publication Number:
  US 20100009007A1
• Time in Patent Office: Days
• US Class Current: 424/499
• CPC Class Codes: A61K 9/5052 Proteins, e.g. albumin
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings

Abstract

The present disclosure is directed to surface-modified microparticles, pharmaceutical compositions thereof, and methods of making and using such particles. The surface-modified microparticles include a microparticle core, and at least one monolayer associated with the microparticle core. The monolayer comprises an amphiphilic polymer or non-ionic polymer grafted to an ionic polymer.

Claims

1. A surface-modified microparticle comprising:

a microparticle core and at least one monolayer associated with the microparticle core;

wherein the monolayer comprises an amphiphilic polymer or a nonionic polymer grafted to an ionic polymer; and

the microparticle core comprises a macromolecule selected from the group consisting of carbohydrates, peptides, proteins, vectors, nucleic acids, complexes thereof, and conjugates thereof.

2. The surface-modified microparticle of claim 1, wherein the amphiphilic polymer or nonionic polymer has a degree of grafting to the ionic polymer of about 1% to about 30%.

3. The surface-modified microparticle of claim 2, wherein the degree of grafting is about 5% to about 25%.

4. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer is selected from the group consisting of polyethylene glycols, poloxamers, carbohydrate-based polymers, polyaliphatic alcohols, polyethylene glycol acrylates, poly(vinyl)polymers, polyethers, polyimides, polyesters, polyaldehydes, and copolymers, mixtures, and derivatives thereof.

5. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer is a carbohydrate-based polymer selected from the group consisting of hydroxyethyl starch polymers, polysialic acid, cyclodextrins, and mixtures thereof.

6. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 500 Da to about 20,000 Da.

7. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 750 Da to about 15,000 Da.

8. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 900 Da to about 10,000 Da.

9. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 1,000 Da to about 5,000 Da.

10. The surface-modified microparticle of claim 1, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 1,500 Da to about 2,500 Da.

11. The surface-modified microparticle of claim 1, wherein the ionic polymer is selected from the group consisting of polyelectrolytes, charged polyaminoacids, charged polysaccharides, charged proteinaceous compounds, charged peptides, and mixtures thereof.

12. The surface-modified microparticle of claim 1, wherein the ionic polymer is a cationic polymer selected from the group consisting of polylysines, polyhistidines, polyornithines, polyhydroxylysines, polyarginines, polyhomoarginines, polyaminotyrosines, protamines, polydiaminobutyric acids, polyethyleneimines, polypropylenimines, polyamino(meth)acrylates, polyaminostyrenes, polyaminoethylenes, poly(aminoethyl)ethylene, polyaminoethylstyrenes, polycitrullines, diethyl amino ethyl celluloses, poly-imino tyrosines, cholestyramine-resins, poly-imino acids, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide, chitosans, poly(amidoamine) dendrimers, and mixtures and derivatives thereof.

13. The surface-modified microparticle of claim 1, wherein the ionic polymer is a cationic polymer comprising a monomer selected from the group consisting of lysine, histidine, ornithine, hydroxylysine, arginine, homoarginine, aminotyrosine, diaminobutyric acid, ethyleneimine, propylenimine, amino(meth)acrylate, aminostyrene, aminoethylene, aminoethylethylene, aminoethylstyrene, citrulline, diethyl amino ethyl glucose, imino tyrosine, (vinylbenzyl)trimethylammonium salts, imino acids, quaternary alkyl ammonium salts, amidoamines, glucosamine, and mixtures and derivatives thereof.

14. The surface-modified microparticle of claim 1, wherein the ionic polymer is a anionic polymer selected from the group consisting of polyaspartic acid, polyglutamic acid, polyacrylic acid, polymethacrylic acid, polymaleic acid, polymaleic acid monoester, heparin sulfate, dextran sulfate, polygalacturonic acid, polyalginate(polyaginic acid), polypectimic acid, polymannuronic acid, polyguluronic acid, polysialic acid, polycarboxymethyl cellulose, polyhyaluronic acid, chondroitin sulfate, chitosan sulfate, glycosaminoglycans, proteoglycans, and mixtures thereof.

15. The surface-modified microparticle of claim 1, wherein the ionic polymer is an anionic polymer comprising a monomer selected from the group consisting of aspartic acid, glutamic acid, acrylic acid, methacrylic acid, maleic acid, maleic acid monoester, heparin sulfate, dextran sulfate, galacturonic acid, alginate (aginic acid), pectimic acid, mannuronic acid, guluronic acid, sialic acid, carboxymethyl glucose, hyaluronic acid, chondroitin sulfate, sulfated glucose, sulfated glucuronic acid, sulfated iduronic acid, sulfated glucosamine, sulfated acetylgalactosamine, glycosaminoglycan-modified amino acids, sulfated carbohydrates, and mixtures thereof.

16. The surface-modified microparticle of claim 1, wherein macromolecule is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an anticancer agent, an anticoagulant, an antigen, an anti-inflammatory agent, a blood clotting factor, a cytokine, an enzyme, an enzyme cofactor, an enzyme inhibitor, a growth differentiation factor, a growth factor, an immunological agent, a parathyroid hormone, a vaccine, and mixtures thereof.

17. The surface-modified microparticle of claim 1, wherein the macromolecule is negatively charged, is positively charged, or has an inducible charge.

18. The surface-modified microparticle of claim 1, wherein the macromolecule is a nucleic acid selected from the group consisting of DNAs, RNAs, plasmids, viral vectors, oligonucleotides, antisense nucleic acids, missense nucleic acids, and a mixtures thereof.

19. The surface-modified microparticle of claim 1, wherein the microparticle core comprises an outer surface carrying a net surface charge and the monolayer associated with the microparticle core carries a net charge that is opposite in sign to the net surface charge of the outer surface.

20. The surface-modified microparticle of claim 1, further comprising a second monolayer, wherein the second monolayer is between the monolayer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer and an outer surface of the microparticle core.

21. The surface-modified microparticle of claim 20, wherein the monolayer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer is adjacent to the second monolayer.

22. The surface-modified microparticle of claim 21, wherein the second monolayer carries a net charge that is opposite in sign to the net charge of the monolayer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer.

23. The surface-modified microparticle of claim 1, wherein the surface-modified microparticle comprises at least first and second monolayers and the net charge of the first monolayer is opposite in sign to the net charge of the second monolayer.

24. The surface-modified microparticle of claim 23, wherein the microparticle core comprises an outer surface carrying a net surface charge, and the layer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer carries a net charge that is the same in sign as the net charge of the microparticle core.

25. The surface-modified microparticle of claim 1, wherein when administered to a subject, the surface-modified microparticle demonstrates at least 50% less cell uptake than a microparticle coated with a non-grafted ionic polymer.

26. The surface-modified microparticle of claim 1, wherein when administered to a subject, the surface-modified microparticle demonstrates at least 85% less cell uptake than a microparticle coated with a non-grafted ionic polymer.

27. The surface-modified microparticle of claim 1, wherein substantially no covalent bonds are present between the macromolecule and the amphiphilic polymer or nonionic polymer.

28. A pharmaceutical composition comprising a plurality of surface-modified microparticles according to claim 1.

29. The pharmaceutical composition of claim 28, wherein the surface-modified microparticles have an average size from about 0.01 μ

m to about 200 μ

m.

30. The pharmaceutical composition of claim 28, wherein the surface-modified microparticles have an average size from about 0.1 μ

m to about 10 μ

m.

31. The pharmaceutical composition of claim 28, wherein the surface-modified microparticles have an average size of from about 0.1 μ

m to about 5 μ

m.

32. The pharmaceutical composition of claim 28, wherein the surface-modified microparticles have a narrow size distribution.

33. The pharmaceutical composition of claim 32, wherein the ratio of a volume diameter of the 90th percentile of the microparticles to the volume diameter of the 10th percentile is less than or equal to about 5.

34. The pharmaceutical composition of claim 28, wherein the microparticles have a dry density of about 0.5 to about 2 g/cm³.

35. The pharmaceutical composition of claim 28, further comprising an excipient.

36. The pharmaceutical composition of claim 28, wherein said microparticles are suitable for pulmonary administration.

37. The pharmaceutical composition of claim 28, wherein said microparticles are suitable for injectable administration.

38. A process of preparing a surface-modified microparticle comprising a grafted polymer comprising:

a) providing a microparticle core comprising a macromolecule selected from the group consisting of carbohydrates, peptides, proteins, vectors, nucleic acids, complexes thereof, and conjugates thereof;

b) admixing (i) an activated amphiphilic or nonionic polymer and (ii) an ionic polymer under conditions sufficient to form a grafted polymer, said grafted polymer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer; and

c) admixing the grafted polymer of (b) and the microparticle core under conditions sufficient to form a surface-modified microparticle comprising a grafted polymer and having an outermost monolayer, said outermost monolayer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer.

39. The process of claim 38, wherein the microparticle core is provided as a surface-modified microparticle.

40. The process of claim 38, wherein the amphiphilic polymer or nonionic polymer has a degree of grafting to the ionic polymer of about 1% to about 30%.

41. The process of claim 40, wherein the degree of grafting is about 5% to about 25%.

42. The process of claim 38, wherein the amphiphilic or nonionic polymer is selected from the group consisting of polyethylene glycols, poloxamers, carbohydrate-based polymers, polyaliphatic alcohols, polyethylene glycol acrylates, poly(vinyl)polymers, polyethers, polyimides, polyesters, polyaldehydes, and copolymers, mixtures, and derivatives thereof.

43. The process of claim 38, wherein the amphiphilic or nonionic polymer is a carbohydrate-based polymer selected from the group consisting of hydroxyethyl starch polymers, polysialic acid, cyclodextrins, and mixtures thereof.

44. The process of claim 38, wherein the ionic polymer is a cationic polymer selected from the group consisting of polylysine, polyhistidine, polyornithine, polyhydroxylysine, polyarginine, polyhomoarginine, polyaminotyrosine, protamine, polydiaminobutyric acid, polyethyleneimine, polypropylenimine, polyamino(meth)acrylate, polyaminostyrene, polyaminoethylene, poly(aminoethyl)ethylene, polyaminoethylstyrene, polycitrulline, diethyl amino ethyl cellulose, poly-imino tyrosine, cholestyramine-resin, poly-imino acid, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide, chitosan, poly(amidoamine) dendrimers, and mixtures thereof.

45. The process of claim 38, wherein the ionic polymer is a cationic polymer comprising a monomer selected from the group consisting of lysine, histidine, ornithine, hydroxylysine, arginine, homoarginine, aminotyrosine, diaminobutyric acid, ethyleneimine, propylenimine, amino(meth)acrylate, aminostyrene, aminoethylene, aminoethylethylene, aminoethylstyrene, citrulline, diethyl amino ethyl glucose, imino tyrosine, (vinylbenzyl)trimethylammonium salts, imino acids, quaternary alkyl ammonium salts, amidoamines, glucosamine, and mixtures and derivatives thereof.

46. The process of claim 38, wherein the ionic polymer is a anionic polymer selected from the group consisting of polyaspartic acid, polyglutamic acid, polyacrylic acid, polymethacrylic acid, polymaleic acid, polymaleic acid monoester, heparin sulfate, dextran sulfate, polygalacturonic acid, polyalginate (polyaginic acid), polypectimic acid, polymannuronic acid, polyguluronic acid, polysialic acid, polycarboxymethyl cellulose, polyhyaluronic acid, chondroitin sulfate, chitosan sulfate, glycosaminoglycans, proteoglycans, and mixtures thereof.

47. The process of claim 38, wherein the ionic polymer is an anionic polymer comprising a monomer selected from the group consisting of aspartic acid, glutamic acid, acrylic acid, methacrylic acid, maleic acid, maleic acid monoester, heparin sulfate, dextran sulfate, galacturonic acid, alginate (aginic acid), pectimic acid, mannuronic acid, guluronic acid, sialic acid, carboxymethyl glucose, hyaluronic acid, chondroitin sulfate, sulfated glucose, sulfated glucuronic acid, sulfated iduronic acid, sulfated glucosamine, sulfated acetylgalactosamine, glycosaminoglycan-modified amino acids, sulfated carbohydrates, and mixtures thereof.

48. The process of claim 38, wherein the amphiphilic or nonionic polymer comprises polyethylene glycol and the polyethylene glycol has a molecular weight of about 500 Da to about 20,000 Da.

49. The process of claim 38, wherein the macromolecule is negatively charged, is positively charged, or has an inducible charge.

50. The process of claim 38, wherein the macromolecule is a nucleic acid selected from the group consisting of DNAs, RNAs, plasmids, viral vectors, oligonucleotides, antisense nucleic acids, missense nucleic acids, and mixtures thereof.

51. The process of claim 38, wherein the macromolecule is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an anticancer agent, an anticoagulant, an antigen, an anti-inflammatory agent, a blood clotting factor, a cytokine, an enzyme, an enzyme cofactor, an enzyme inhibitor, a growth differentiation factor, a growth factor, an immunological agent, a parathyroid hormone, a vaccine, and mixtures thereof.

52. A surface-modified microparticle comprising:

a microparticle core and at least one monolayer associated with the microparticle core;

wherein the monolayer comprises an amphiphilic polymer or a nonionic polymer grafted to an ionic polymer; and

the microparticle core comprises a macromolecule.

53. The microparticle of claim 52, wherein the macromolecule is an active agent.

54. The microparticle of claim 52, wherein the macromolecule has a molecular weight of at least 2 kD.

55. The microparticle of claim 52, wherein the macromolecule comprises a modifiable functional group.

56. The microparticle of claim 55, wherein the modifiable functional group is selected from the group consisting of an amino group, a carboxyl group, a thiol group, a hydroxyl group, an epoxy group, a haloalkyl group, an aldehyde group, a carbonyl group, an isocyanate group, an imino group, a nitrile group, and combinations thereof.

57. A process of preparing a surface-modified microparticle comprising a grafted polymer comprising:

a) providing a microparticle core comprising an active agent;

b) admixing (i) an activated amphiphilic or nonionic polymer and (ii) an ionic polymer under conditions sufficient to form a grafted polymer, said grafted polymer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer; and

c) admixing the grafted polymer of (b) and the microparticle core under conditions sufficient to form a surface-modified microparticle comprising a grafted polymer and having an outermost monolayer, said outermost monolayer comprising the amphiphilic polymer or nonionic polymer grafted to the ionic polymer.

58. The process of claim 57, wherein the active agent comprises a small molecule having a molecular weight less than 2 kD.

59. The process of claim 57, wherein the active agent comprises a macromolecule having a molecular weight of at least 2 kD.

60. The process of claim 57, wherein the active agent comprises a modifiable functional group.

61. The process of claim 60, wherein the modifiable functional group is selected from the group consisting of an amino group, a carboxyl group, a thiol group, a hydroxyl group, an epoxy group, a haloalkyl group, an aldehyde group, a carbonyl group, an isocyanate group, an imino group, a nitrile group, and combinations thereof.